FDA fast-track approval for rare child sickness becomes permanent.
H.R. 10359 — Priority for Pediatric Cures Act · Filed by Gus Bilirakis (R-FL) · 5 cosponsors · Introduced Sep 14, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The bill makes permanent the FDA's power to give priority review vouchers. These vouchers let drug makers get FDA approval faster. The vouchers are for drugs that treat rare sickness in children. Right now this power has an end date. The bill removes that end date.
Who it affects
Drug makers that develop treatments for rare child sickness may benefit. Children with rare sickness might get new treatments faster. The bill does not require these drugs to be cheap or easy to get.
One thing to notice
Priority review vouchers can be bought and sold between drug makers. Making this program permanent means Congress will not review it again without passing a new law.
From the analysis of the bill text, linked under Primary records below.
Where it stands
5 cosponsors: 3 Democrats, 2 Republicans.
- Sep 14, 2026 — Introduced · Congress.gov: “Introduced in House”
- Sep 14, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Words to know
- rare sickness in children — Uncommon health problems that affect kids.
- drug makers — Businesses that make and sell medicines.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (278 characters) on Sep 16, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,342 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-09-18.
“FDA fast-track approval for rare child sickness becomes permanent.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr10359/simple Report an error